Health AstraZeneca Pays $185M to Add Oral GLP-1 Drug Candidate to Pipeline January 17, 2024 176 TelecomApril 3, 2026Democrat rips Polymarket for taking bets on fate of US pilot shot down over Iran TelecomApril 3, 2026A third of Americans planning to invest in high-risk, speculative assets: Study TelecomApril 3, 2026Anthropic launches new corporate PAC to ramp up election spending TelecomApril 3, 2026FBI labels data breach ‘major incident,’ notifies Congress TelecomApril 3, 2026Palantir-linked campaign donations put Democrats in tight spot AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight. Prime Plus Facebook Twitter Pinterest WhatsApp SportsApril 4, 2026Lakers Hit With More Bad News on Luka Doncic Hamstring Injury Sports Lakers’ Title Odds Collapse After Luka Doncic Suffers Brutal Blow April 4, 2026 Sports Jalen Williams Declares Feelings for Fans Bored with Thunder’s Success April 4, 2026 Sports Lakers Draft Pick Shines as South Bay Advances in G League Playoffs April 4, 2026
